Literature DB >> 20485337

Covariate analysis of QTc and T-wave morphology: new possibilities in the evaluation of drugs that affect cardiac repolarization.

C Graff1, J J Struijk, J Matz, J K Kanters, M P Andersen, J Nielsen, E Toft.   

Abstract

This study adds the dimension of a T-wave morphology composite score (MCS) to the QTc interval-based evaluation of drugs that affect cardiac repolarization. Electrocardiographic recordings from 62 subjects on placebo and 400 mg moxifloxacin were compared with those from 21 subjects on 160 and 320 mg D,L-sotalol. T-wave morphology changes, as assessed by DeltaMCS, are larger after 320 mg D,L-sotalol than after 160 mg D,L-sotalol; and the changes associated with 160 mg D,L-sotalol are, in turn, larger than those associated with moxifloxacin and placebo. Covariate analyses of DeltaQTc and DeltaMCS showed that changes in T-wave morphology are a significant effect of D,L-sotalol. By contrast, moxifloxacin was found to have no significant effect on T-wave morphology (DeltaMCS) at any given change in QTc. This study offers new insights into the repolarization behavior of a drug associated with low cardiac risk vs. one associated with a high risk and describes the added benefits of a T-wave MCS as a covariate to the assessment of the QTc interval.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20485337     DOI: 10.1038/clpt.2010.51

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

1.  The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs.

Authors:  Tanveer A Bhuiyan; Claus Graff; Jørgen K Kanters; Jimmi Nielsen; Jacob Melgaard; Jørgen Matz; Egon Toft; Johannes J Struijk
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 2.  Assessing QT interval prolongation and its associated risks with antipsychotics.

Authors:  Jimmi Nielsen; Claus Graff; Jørgen K Kanters; Egon Toft; David Taylor; Jonathan M Meyer
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

3.  Minimal T-wave representation and its use in the assessment of drug arrhythmogenicity.

Authors:  Saeed Shakibfar; Claus Graff; Jørgen K Kanters; Jimmi Nielsen; Samuel Schmidt; Johannes J Struijk
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-10-27       Impact factor: 1.468

4.  Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study.

Authors:  Claus Graff; Johannes J Struijk; Jørgen K Kanters; Mads P Andersen; Egon Toft; Benoît Tyl
Journal:  Clin Drug Investig       Date:  2012-05-01       Impact factor: 2.859

5.  Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Authors:  Jørgen Matz; Claus Graff; Petri J Vainio; Antero Kallio; Astrid Maria Højer; Johannes J Struijk; Jørgen K Kanters; Mads P Andersen; Egon Toft
Journal:  Clin Drug Investig       Date:  2011-11-01       Impact factor: 2.859

6.  Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.

Authors:  A John Camm; Onur N Karayal; Herbert Meltzer; Sheela Kolluri; Cedric O'Gorman; Jeffrey Miceli; Thomas Tensfeldt; John M Kane
Journal:  CNS Drugs       Date:  2012-04-01       Impact factor: 5.749

7.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

8.  Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial.

Authors:  Boukje C Eveleens Maarse; Claus Graff; Jørgen K Kanters; Michiel J van Esdonk; Michiel J B Kemme; Aliede E In 't Veld; Manon A A Jansen; Matthijs Moerland; Pim Gal
Journal:  Br J Clin Pharmacol       Date:  2021-08-24       Impact factor: 3.716

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.